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PACING

Atrioventricular Synchronous Pacing
Using a Leadless Ventricular Pacemaker
Results From the MARVEL 2 Study
Clemens Steinwender, MD,a,b Surinder Kaur Khelae, MD,c Christophe Garweg, MD,d Joseph Yat Sun Chan, MD,e
Philippe Ritter, MD,f Jens Brock Johansen, MD, PHD,g Venkata Sagi, MD,h Laurence M. Epstein, MD,i
Jonathan P. Piccini, MD, MHS,j Mario Pascual, MD,k Lluis Mont, MD,l Todd Sheldon, MS,m Vincent Splett, MS,m
Kurt Stromberg, MS,m Nicole Wood, BS,m Larry Chinitz, MDn
ABSTRACT
OBJECTIVES This study reports on the performance of a leadless ventricular pacemaker with automated, enhanced
accelerometer-based algorithms that provide atrioventricular (AV) synchronous pacing.
BACKGROUND Despite many advantages, leadless pacemakers are currently only capable of single-chamber ventricular pacing.
METHODS The prospective MARVEL 2 (Micra Atrial tRacking using a Ventricular accELerometer 2) study assessed the
performance of an automated, enhanced accelerometer-based algorithm downloaded to the Micra leadless pacemaker
for up to 5 h in patients with AV block. The primary efﬁcacy objective was to demonstrate the superiority of the algorithm
to provide AV synchronous (VDD) pacing versus VVI-50 pacing in patients with sinus rhythm and complete AV block. The
primary safety objective was to demonstrate that the algorithm did not result in pauses or heart rates of >100 beats/min.
RESULTS Overall, 75 patients from 12 centers were enrolled; an accelerometer-based algorithm was downloaded to
their leadless pacemakers. Among the 40 patients with sinus rhythm and complete AV block included in the primary
efﬁcacy objective analysis, the proportion of patients with $70% AV synchrony at rest was signiﬁcantly greater with VDD
pacing than with VVI pacing (95% vs. 0%; p < 0.001). The mean percentage of AV synchrony increased from 26.8%
(median: 26.9%) during VVI pacing to 89.2% (median: 94.3%) during VDD pacing. There were no pauses or episodes of
oversensing-induced tachycardia reported during VDD pacing in all 75 patients.
CONCLUSIONS Accelerometer-based atrial sensing with an automated, enhanced algorithm signiﬁcantly improved AV
synchrony in patients with sinus rhythm and AV block who were implanted with a leadless ventricular pacemaker. (Micra
Atrial Tracking Using a Ventricular Accelerometer 2 [MARVEL 2]; NCT03752151). (J Am Coll Cardiol EP 2020;6:94–106)
© 2020 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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P

Atrioventricular Synchronous Leadless Pacing

ermanent cardiac pacing has provided sub-

accelerometer-based

stantial beneﬁts for millions of patients with

feasible and signiﬁcantly improved AV syn-

atrial

sensing

was

bradyarrhythmias since its introduction in the

chrony in patients with AV block and a Micra

1950s. For many decades, cardiac pacing has been

single-chamber leadless pacemaker implan-

exclusively performed by systems consisting of subcu-

ted in the right ventricle (9,10). Based upon

taneously implanted pulse generators with $1 trans-

results

venous leads. However, approximately 1 in 8 patients

tRacking using a Ventricular accELerometer)

treated with these traditional pacing systems experi-

study, enhancements were made to the algo-

from

the

MARVEL

(Micra

Atrial

ABBREVIATIONS
AND ACRONYMS
AV = atrioventricular
CI = conﬁdence interval
ECG = electrocardiogram
EGM = electrogram
LVOT-VTI = left ventricular
outﬂow tract velocity-time

ences a complication attributed to the pacemaker

rithm, including automated programming

pocket or leads, such as hematoma, pneumothorax, hemo-

features and mode switching algorithms to

thorax, lead dislodgement, lead failure, or infection (1).

accommodate changes in patient rhythm and activity.

integral

We report on the performance of this enhanced algo-

SEE PAGE 107

rithm to provide AV synchronous pacing in patients
Leadless pacemakers were developed to overcome

with persistent third-degree (complete) AV block and

pocket- and lead-related complications. Results from

normal sinus rhythm implanted with a Micra leadless

the Micra Transcatheter Pacing Study and Micra Post

pacemaker in the right ventricle.

Approval Registry demonstrated a high implantation
success rate and a low major complication rate, with a

METHODS

>60% reduction in complications versus transvenous
pacemakers (2–4). These encouraging results have led

STUDY DESIGN. The MARVEL 2 study was a prospec-

to an increased interest in a broader use of leadless

tive, nonrandomized multicenter clinical trial. The

pacemakers; however, currently available leadless

primary aim of the MARVEL 2 study was to conﬁrm the

pacemakers only provide single-chamber ventricular

ability of an enhanced downloadable algorithm

rate responsive pacing.

(hereafter referred to as the MARVEL 2 algorithm) to

Use of transvenous single-chamber ventricular

provide AV synchronous pacing by mechanically

pacemakers is limited to <15% of the pacemaker pop-

sensing atrial contractions via the accelerometer signal

ulation (5). Patients with sinus rhythm and atrioven-

(VDD pacing) from a Micra leadless pacemaker

tricular (AV) block have been shown to beneﬁt from

implanted in the right ventricle. A detailed description

dual-chamber pacemakers that can provide AV syn-

of the algorithm is provided in the Online Appendix.

chrony (6–8). Previous proof-of-concept studies tested

Brieﬂy, the algorithm uses signal components from the

the performance of an AV synchronous algorithm

Micra accelerometer corresponding to passive ven-

downloaded into an already implanted Micra device

tricular ﬁlling (A3) and atrial contraction (A4) to pro-

(Model MC1VR01; Medtronic, Inc, Minneapolis, Min-

vide AV synchronous pacing (Online Figure S1). In

nesota) that detected atrial contractions using the

addition, 2 mode switching algorithms enable auto-

device’s

Results

matic switching to VVI-40 and VVIR pacing. Approval

from early feasibility studies demonstrated that

of the study protocol by local ethics committees and

built-in

3-axis

accelerometer.
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national regulatory agencies was sought at each

patients, the MARVEL 2 software was removed

participating institution. All patients provided written

following each evaluation time point. Evaluation of

informed consent.

algorithm performance in these patients allowed the
MARVEL 2 features to be tested at multiple points in

PATIENTS AND PROCEDURES. The MARVEL 2 study

enrolled patients with a history of AV block (including
patients with normal sinus function and complete AV
block) who were age 18 years or older and were previously

implanted

or

undergoing

implantations

(newly implanted patients) with a Micra pacemaker
that had a remaining projected device longevity of $6
years. Following informed consent, baseline procedures were performed, and medical history obtained.
Most enrolled patients completed the study procedures during a single study visit. However, patients
who enrolled in the study at the time of their Micra
implantation (newly implanted patients) had the algorithm downloaded and completed the study procedures after Micra implantation, but before hospital
discharge (pre-hospital discharge) and approximately
1-month post-implantation. At the study visit(s), the
algorithm was downloaded into the patient’s implanted device, and a specialized Holter monitor capable of
storing

accelerometer

waveforms,

electrograms

(EGMs), device markers, and electrocardiogram (ECG)
data was placed for the duration of the study procedures. Initial algorithm parameter settings, including

the device life cycle.
ENDPOINTS. The

primary efﬁcacy endpoint was

deﬁned as a paced or sensed ventricular beat within
300 ms following a surface ECGconﬁrmed P-wave for
at least 70% of ECGconﬁrmed P-waves. For each patient, the primary efﬁcacy endpoint was evaluated
during the auto-setup phase, which occurred during
VVI pacing, and during the resting phase, which
occurred during VDD pacing. The primary safety
endpoint was deﬁned as freedom from pauses lasting
>2 cardiac cycles (deﬁned by the programmed lower
rate

interval)

and

freedom

from

episodes

of

oversensing-induced tachycardia >100 beats/min for
>3 min. The secondary endpoint was LVOT-VTI as
obtained from echocardiogram while the algorithm
was programmed to VVI mode and VDD mode. All
enrolled patients who had the investigational algorithm was downloaded to their devices were assessed
for the primary safety endpoint, whereas the subset of
patients with complete AV block and normal sinus
function were evaluated for the primary efﬁcacy and
secondary endpoints.

accelerometer vector combination, A3 end time, A3

STATISTICAL METHODS. A priori determination of

threshold, and A4 threshold, were set by the algorithm

sample size indicated that 35 patients with normal

auto-setup feature during VVI-50 pacing. Following

sinus node function and complete AV block would

auto-setup, the algorithm parameters were adjusted to

provide >90% power to test the primary efﬁcacy

optimize A4 detection, if needed.

endpoint, assuming $50% of patients would have

After the algorithm parameters were set, the pac-

discordant results between pacing modes and $90%

ing mode was programmed to VDD, and the patient

of discordant results would favor algorithm-mediated

rested in a supine or sitting position for approxi-

VDD pacing. A sample size of 70 patients (with any

mately 20 min. Following the resting period, the pa-

predominant rhythm) provided 90% power to test the

tient assumed a series of postures (supine, lying on

primary safety endpoint against a predeﬁned perfor-

right side, lying on left side, sitting, and standing) for

mance goal of 87%, assuming the true underlying

2 min each. In addition, patients walked at a

endpoint rate exceeded 98%. Finally, a sample size of

comfortable and vigorous pace for 2 min to promote

35 patients with normal sinus node function and

an activity mode switch.

complete AV block provided 89% power to test for a

Echocardiograms were collected from each patient

difference in LVOT-VTI between pacing modes,

during both VVI and VDD pacing following a stan-

assuming a mean difference that favored algorithm

dardized echo protocol. An echocardiography core

VDD pacing of 2.1  3.8 cm. All sample size calcula-

laboratory (United Heart and Vascular Clinic, St. Paul,

tions assumed a 2-sided type I error rate of 5%.

Minnesota), blinded to patient and pacing mode,
measured

the

left

ventricular

outﬂow

Each patient’s predominant heart rhythm was

(LVOT)

determined as complete AV block with normal sinus

velocity-time integral (VTI) during 6 cardiac cycles in

function, intact AV conduction, or other (e.g., atrial

each pacing mode.

arrhythmias, sinus node dysfunction, other AV block)

In addition to the preceding procedures, newly
implanted patients had the algorithm downloaded to

based on PR intervals (during auto-setup) and PP intervals during the auto-setup and resting phases.

their devices; they underwent Holter monitoring and

For each cardiac cycle, AV synchrony status was

completed the auto-setup procedure immediately

determined as described in the Online Appendix. AV

following device implantation. For newly implanted

synchrony percentage was calculated for each patient
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T A B L E 1 Patient Baseline Characteristics

Enrolled
(n ¼ 77)

Downloaded MARVEL 2
Software
(n ¼ 75)

Evaluable for Primary
Efﬁcacy Objective
(n ¼ 40)

77.6  11.8

77.5  11.8

76.7  12.9

81.0

81.0

80.0

31 (40.3)

30 (40.0)

22 (55.0)

13.7  14.5

13.8  14.6

14.6  16.6

9.7

9.7

9.3

Hypertension

53 (68.8)

52 (69.3)

28 (70.0)

Atrial ﬁbrillation

14 (18.2)

14 (18.7)

3 (7.5)

Diabetes

14 (18.2)

13 (17.3)

6 (15.0)

Coronary artery disease

Age, yrs
Mean  SD
Median
Female
Months from Micra implantation
Mean  SD
Median
Comorbidities

23 (29.9)

23 (30.7)

8 (20.0)

COPD

7 (9.1)

7 (9.3)

4 (10.0)

Dialysis

3 (3.9)

3 (4.0)

1 (2.5)

RV apex

12 (15.6)

12 (16.0)

8 (20.0)

RV high septum

11 (14.3)

11 (14.7)

7 (17.5)

RV mid-septum

27 (35.1)

26 (34.7)

11 (27.5)

RV low septum

12 (15.6)

12 (16.0)

8 (20.0)

RVOT

12 (15.6)

12 (16.0)

4 (10.0)

Other

2 (2.6)

2 (2.7)

2 (5.0)

Not reported

1 (1.3)

0 (0.0)

0 (0.0)

Complete AV block with normal sinus function

40 (51.9)

40 (53.3)

40 (100.0)

Intact AV conduction

18 (23.4)

18 (24.0)

0 (0.0)

Other rhythm

15 (19.5)

15 (20.0)

0 (0.0)

Device location

Predominant rhythm*

Indeterminate rhythm†

2 (2.6)

2 (2.7)

0 (0.0)

Patient exited before software download

2 (2.6)

0 (0.0)

0 (0.0)

Values are mean  SD and n (%). *Predominant rhythm at pre-hospital discharge visit for 10 newly implanted patients. †Noise on surface electrocardiographic signal prevented
assessment of predominant rhythm.
AV ¼ atrioventricular; COPD ¼ chronic obstructive pulmonary disease; RV ¼ right ventricular; RVOT ¼ right ventricular outﬂow tract.

during the auto-setup and resting phases by dividing

the expected AV synchrony proportion based on the

the number of synchronous cycles by the total num-

logistic model and the median percentage were

ber of cardiac cycles. The primary efﬁcacy analysis

reported.

cohort included patients with complete AV block

Holter recordings from all patients were assessed for

and normal sinus rhythm who had at least 500

the primary safety endpoint using both programmatic

evaluable cardiac cycles during the auto-setup and

and manual review. The proportion of patients who

resting phases. For newly implanted patients, the

met the primary safety endpoint was compared with

pre-hospital discharge visit was used. McNemar’s test

the performance goal using an exact binomial test.

was used to compare the proportion of patients

A paired Student’s t-test was used to evaluate the

with $70% AV synchrony during VVI and VDD pacing,

change in mean LVOT-VTI between VVI and VDD

respectively. In addition, AV pacing percentages and

modes in patients with complete AV block and normal

atrial detection rates were compared between pacing

sinus

modes and estimated during each posture and ma-

measurements.

rhythm

after

averaging

LVOT-VTI

across

neuver using logistic regression models that incor-

Type I error was controlled at the 0.05 level for

porated generalized estimating equations to account

analysis of the primary and secondary endpoints us-

for correlation in algorithm performance within each

ing a hierarchical closed testing procedure.

patient. Similar models were used to compare AV
Synchrony percentage

between

the

study

visits

pre-hospital

In a post hoc analysis, sinus rates computed between successive PP intervals were compared be-

newly

tween the last 5 min of VVI and VDD pacing during

implanted patients. Due to skewness observed in AV

the auto-setup and resting periods in patients who

synchrony proportions of individual patients, both

were evaluated for the primary efﬁcacy endpoint

discharge

and

1-month

for
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C E N T R A L IL L U ST R A T I O N AV Synchronous Pacing Percentage

100
94.3%
89.2%

AV Synchronous Pacing Percentage

98

80

60

40
26.8%

20

0
VDD

VVI-50
Pacing Mode
Steinwender, C. et al. J Am Coll Cardiol EP. 2020;6(1):94–106.

Atrioventricular (AV) synchronous pacing percentage during auto-setup (VVI-50 mode) and resting (VDD mode) in 40 patients with complete
AV block and normal sinus rhythm. Gray lines indicate individual patients. Blue line connects average AV synchrony percentage and the red
line connects medians. Error bars are 95% conﬁdence intervals. Black dashed line is the primary objective of 70%. During VVI-50 pacing, 0%
of patients had $70% AV synchrony, during VDD pacing 95% had $70% AV synchrony (p < 0.001).

using a repeated measures analysis of variance

patients were enrolled on the day of implantation and

model. Statistical analyses were performed using SAS

were considered newly implanted patients. The most

version 9.4 (SAS Institute, Cary, North Carolina) or R

common primary pacing indication was third-degree

software (R Foundation, Vienna, Austria).

AV block without atrial arrhythmias (n ¼ 47; 61.0%).
Of the 77 enrolled patients, 40 (51.9%) had a predom-

RESULTS

inant rhythm of complete AV block with normal sinus
function during Holter monitoring during the MARVEL

PATIENTS. A total of 77 patients from 12 centers in

2 procedure (pre-hospital discharge visit for newly

Europe, Malaysia, Hong Kong, and the United States

implanted patients) and were eligible for inclusion in

were enrolled in the MARVEL 2 study. Of the

the primary efﬁcacy objective (Online Figure S2). The

77 enrolled patients, 75 devices received the software

remaining patients had a predominant rhythm of

download, and 74 (96%) patients completed the study

intact AV conduction (n ¼ 18; 23.4%), other rhythm

procedures, with 1 exiting after the software down-

(n ¼ 15; 19.5%), or indeterminate rhythm due to poor

load, but before completing the echocardiographic

ECG quality (n ¼ 2; 2.6%) and were not included in the

procedure to evaluate LVOT-VTI. Average age of the

primary efﬁcacy objective analysis.

enrolled patients was 77.6  11.8 years (range 21 to 94

EFFICACY RESULTS. All 40 patients with a predom-

years), and 31 (40%) patients were women. Patients

inant rhythm of complete AV block with normal sinus

had been implanted with a Micra device for a median of

rhythm were included in the primary efﬁcacy anal-

9.7 months (range 0 to 62.1 months) (Table 1). Ten

ysis. AV synchrony percentage increased from an

JACC: CLINICAL ELECTROPHYSIOLOGY VOL. 6, NO. 1, 2020
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F I G U R E 1 Distribution of P-V Intervals

Distribution of P-V intervals during auto-setup (VVI-50 mode) and during resting (VDD mode) for 4 patients with percentage of atrioventricular
(AV) synchrony during VDD pacing ranging from 99.7% to 33.4%. Red dashed line indicates 300 ms.
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100

F I G U R E 2 AV Synchrony Percentage by Maneuver

89.2%
86.7%

86.5%

80

83.5%
75.4%

74.7%

60
40
20

AV Synchrony Percentage

72.7%
69.8%

n=

40

39

38

39

Supine

Left
Lateral

Right
Lateral

39

36

32

23

Sitting

Standing

Normal Walk

Fast Walk

0

100

20-min
Resting

Maneuver

AV synchrony percentage by maneuver for patients with complete AV block and normal sinus function. Error bars represent 95% conﬁdence
intervals. Abbreviation as in Figure 1.

average of 26.8% (95% conﬁdence interval [CI]: 26.2%

During posture and maneuver testing assessed

to 27.5%; median: 26.9%) to 89.2% (95% CI: 84.8% to

over 2 min each among all 40 patients, AV synchrony

92.5%; median: 94.3%) during VVI-50 and VDD pac-

ranged from 89.2% during the resting period to 69.8%

ing, respectively (Central Illustration). Zero patients

while standing (Figure 2). During the resting period,

had $70% AV synchrony during VVI-50 pacing,

the ability of the rate smoothing operation to main-

whereas 38 (95%) had $70% AV synchrony during

tain synchrony during intermittent A4 undersensing

algorithm-mediated VDD pacing (p < 0.001 for pro-

allowed the AV synchrony percentage to exceed

portion of patients with $70% synchrony). The dis-

the

tribution of P-wave to V-event (PV) intervals during

(Online Figure S3). There was no association between

VVI-50 pacing were generally uniform between

AV synchrony percentage and time since implanta-

0 and 1,200 ms, whereas they were peaked and

tion (Online Figure S4). There was also no evidence to

centered at values <300 ms during VDD pacing

suggest that the percentage of AV synchrony differed

(Figure 1). The 2 patients who failed to meet the pri-

by physician-reported Micra implantation location

mary efﬁcacy endpoint during VDD pacing were from

(p ¼ 0.287).

A4

detection

rate

(89.2%

vs.

80.3%)

2 different centers and had AV synchrony percentages

Among patients with intact AV conduction, the

of 68.6% and 33.4%, respectively. The ﬁrst patient

mean AV synchrony percentage was 74.8% (95% CI:

had low and variable amplitude A4 signals. The

53.6% to 88.4%; median 98.9%) during VVI-50 pacing

accelerometer signals for the second patient were

and 79.6% (95% CI: 59.1% to 91.3%; median: 99.7%)

exempliﬁed by small signals related to both atrial and

during VDD pacing. There were 2 patients with long

ventricular contraction (i.e., small A4 and A1 signals,

PV intervals, with >97% of PV intervals >300 ms (pre-

respectively) and large signals during passive ven-

speciﬁed deﬁnition of synchrony); therefore, both

tricular ﬁlling (A3). Notably, this patient had a history

patients had <3% AV synchrony in both pacing

of repaired tetralogy of Fallot in childhood with pul-

modes. Of the 15 patients with other rhythms, 7 had

monary valve replacement.

visible P waves conﬁrmed and/or detected. The
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F I G U R E 3 LVOT-VTI During VVI-50 and VDD Pacing

Left ventricular outﬂow tract velocity-time integral (LVOT-VTI) (cm) during VVI-50 and VDD pacing in 39 patients with complete AV block and
normal sinus function. (Left) LVOT-VTI during VVI-50 and VDD pacing for individual patients (gray lines) and on average (blue lines). (Right)
Absolute change in LVOT-VTI during VDD relative to VVI-50 pacing for individual patients (red circles) and on average (blue circle). Error bars
represent 95% conﬁdence intervals. BPM ¼ beats per minute.

remaining 8 had no visible P-waves due to atrial

ventricular pacing at 67 beats/min (interquartile

ﬁbrillation or atrial ﬂutter. For the 7 patients with

range: 66 to 67 beats/min). Among the 10 newly

other rhythms and identiﬁable P-waves, mean AV

implanted patients, the mean AV synchrony per-

synchrony increased from 41.3% (95% CI: 24.6% to

centage was not signiﬁcantly different between the

60.3%; median: 37.7%) during VVI-50 pacing to 70.2%

pre-hospital discharge and 1-month visit (p ¼ 0.329).

(95% CI: 42.3% to 88.4%; median: 89.3%) during VDD

For additional details on algorithm performance in

pacing. In patients with atrial ﬁbrillation, the A4

the newly implanted patients, refer to the Online

accelerometer signal was of low amplitude, and there

Appendix and Online Figure S5.

was infrequent sensing, which resulted in median

Among the 40 patients with complete AV block and

ventricular pacing at the lower rate (50 beats/min). In

normal sinus rhythm, 39 had paired echocardio-

the patient with atrial ﬂutter, the accelerometer

graphic data available for analysis. LVOT-VTI as a

signal was intermittently detected, which resulted in

proxy of left ventricular stroke volume increased by
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F I G U R E 4 Sinus Rate During VVI-50 and VDD Pacing

Sinus rate during VVI-50 and VDD pacing in 40 patients with complete AV block and normal sinus function. (Left) Sinus rate during VVI-50 and
VDD pacing for individual patients (gray lines) and on average (blue lines). (Right) Change in sinus rate during VDD relative to VVI-50 pacing
for individual patients (red circles) and on average (blue circle). Error bars represent 95% conﬁdence intervals. BPM ¼ beats per minute; other
abbreviation as Figure 1.

1.7 cm (95% CI: 0.7 to 2.7 cm; p ¼ 0.002) or 8.8  15.4%

MODE SWITCHING. All Holter ﬁles from the 75 pa-

during VDD pacing from a baseline average of 22.7 cm

tients who had the algorithm was downloaded to their

(95% CI: 21.0 to 24.4 cm) during VVI pacing (Figure 3).

devices were reviewed to identify both AV conduc-

Similar results were observed for the 15 patients with

tion and activity mode switches. During the entire

other predominant heart rhythms (mean increase:

Holter recording period, there were 470 AV conduc-

2.4 cm; 95% CI: 0.9 to 4.0 cm, during VVI pacing over

tion mode switches in 73 patients. During these mode

an average 22.0 cm during VDD pacing).

switches, the pacing mode remained in VVI-40, pro-

For the 40 patients with complete AV block and

moting intrinsic AV conduction and functioning as

normal sinus rhythm, the sinus rate decreased from

intended. Figure 5A shows an example of a patient

an average of 73.0 beats/min during VVI-50 pacing to

with intermittent third-degree AV block with an AV

66.2 beats/min during VDD pacing (p < 0.001)

mode switch from VVI-40 to VDD when AV block

(Figure 4).

occurred. There were 41 activity mode switch
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F I G U R E 5 AV Conduction Mode Switch and Activity Mode Switch

(A) AV conduction mode switch in patient with intermittent third-degree AV block. Before the mode switch at 2,884 s, the patient exhibits AV
conduction in VVI-40 mode. The patient then goes into second-degree AV block, and the device mode-switches to VDD. Two cycles after the
mode switch, the device begins tracking the atrium in VDD mode. (B) Activity mode switch in patient with complete AV block and normal sinus
rhythm. During the standing and/or walking maneuvers, good AV synchrony is indicated by the similarity of median heart rate (HR) and sinus
rate. Mode switch to VVIR occurs when the sensor rate diverges from the pacing rate. The sensor rate decreases to the median HR and gradually
increases to minimize large rate changes. After the activity ceases, the mode returns to VDD promoting AV synchronous pacing. ADL ¼ activities
of daily living; AS ¼ atrial sense; ECG ¼ electrocardiogram; MS ¼ mode switch; VE ¼ ventricular end; VEGM ¼ ventricular electrogram;
VP ¼ ventricular pace; VS ¼ ventricular sense; other abbreviations as in Figures 1 and 4.

episodes observed in 26 patients. Among the 41 ac-

pacing support during the hall walk exercise and the

tivity mode switches, the median duration of VVIR

activity mode switch operated as intended. The

pacing was 191.7 s. Figure 5B shows an example of an

automatic algorithm was effective in choosing the

activity mode switch in a patient with complete AV

appropriate accelerometer vector(s), A3 threshold,

block and normal sinus rhythm. Examination of each

and A4 threshold, and adjusted the parameters

activity mode switch episode showed appropriate

throughout the study (see Online Appendix).
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SAFETY RESULTS. Among the 75 patients who had

signal due to decreased venous return during the

the algorithm downloaded, there were a total of 95

postural change and the limited 2-min postural

Holter recordings (newly implanted patients had 3

testing period. We found no evidence of a relation-

Holter recordings) that included 647,384 cardiac cy-

ship between time since implantation and the ability

cles for the primary safety endpoint analysis. There

for the algorithm to produce a high percentage of AV

were no instances of ventricular pauses and no in-

synchrony. Speciﬁcally, the performance of the algo-

stances of oversensing-induced tachycardia; there-

rithm did not appear to have diminished efﬁcacy in

fore, all 75 patients (100%) whose devices were

newer implantations versus long-term implantations.

downloaded with the algorithm met the primary

These encouraging results reafﬁrmed the observa-

safety endpoint. The lower 2-sided CI was 95.2%,

tions from those previously reported in the MARVEL

which exceeded the performance goal of 87%; there-

trial, which also demonstrated an increase in AV

fore, the primary safety objective was met (p < 0.001).

synchrony and stroke volume with VDD pacing (9).

Among the 77 enrolled patients, 6 adverse events

A preliminary proof-of-concept study that used a

were reported in 5 patients. Of the 6 adverse events,

simpler algorithm reported an average AV synchrony

none were considered by the investigator to be

of 80.0% in patients with AV block during VDD pacing,

related to the algorithm or procedures. There was 1

with 72.7% having $70% synchrony (9). Following this

event (right atrial hematoma) that was discovered

study, enhancements were made to the algorithm to

during echocardiography and was considered to have

improve detection in patients with low A4 signals,

a probable relationship to the Micra device. This

including an enhanced ﬁlter for atrial signal sensing

adverse event was noted 4.8 months after Micra im-

and the ability to use a combination of 2 different

plantation on the day of the MARVEL 2 study pro-

accelerometer vectors. These enhancements, along

cedures

the

with auto-adjusting detection parameters, might

investigator. The patient was hospitalized for obser-

explain the higher proportion of patients with $70%

vation, but no clinical actions were reported during

AV synchrony observed in the MARVEL 2 study.

and

was

considered

serious

by

the course of the study.

Cardiac output is reduced in patients with complete

DISCUSSION

AV

block

and

slow

ventricular

response

compared with normal resting heart rates, despite
compensatory mechanisms, including increased si-

There were several important ﬁndings from this study

nus rates and stroke volumes (11). It is a well-known

of AV synchronous pacing in patients with single-

phenomenon that restoration of heart rate with a

chamber

pacemakers

pacemaker to a more physiological level results in

capable of accelerometer-based atrial sensing. First,

decreased sympathetic tone and lower sinus rates.

the automated, enhanced MARVEL 2 algorithm

The signiﬁcantly lower sinus rate observed with VDD

right

ventricular

leadless

robustly tracked mechanical atrial contraction and

pacing compared with VVI-50 pacing likely reﬂects a

facilitated AV synchrony. Speciﬁcally, the study

similar physiological phenomenon, with more physi-

intervention improved median AV synchrony from

ological AV synchrony and ventricular rates reducing

27% with VVI pacing to 94% in VDD pacing mode, with

sympathetic tone and sinus rates. The observed

95% of the cohort (38 of 40 patients with complete AV

reduction in sinus rates and the improvement in

block) achieving $70% AV synchronous pacing. Sec-

LVOT-VTI demonstrated the positive impact of AV

ond, the VDD pacing algorithm improved ventricular

synchronous pacing in patients with complete AV

performance 9% as measured by LVOT-VTI, a proxy for

block.

left ventricular stroke volume. Finally, during the

Inhibition of ventricular pacing in patients with

study period, the algorithm proved safe, with no in-

intrinsic AV conduction and sensor-based VVIR pac-

stances of pauses or oversensing-induced tachycardia,

ing during exercise were reliably delivered by 2

regardless of predominant heart rhythm.

different mode-switching algorithms implemented in

AV synchrony was best achieved at rest. Mainte-

the MARVEL 2 algorithm. The intact AV conduction

nance of high AV synchrony at high sinus rates could

mode switch (Figure 5A) regularly checks for intrinsic

be complicated by superposition of accelerometer

AV conduction. This feature was developed to limit

signals related to the atrial contraction with early

pacing to the minimum amount necessary, and in

periods of ventricular ﬁlling. Sitting and standing

turn, to prevent conﬂicts between pacing triggered by

postures demonstrated a decrease in AV synchrony,

the algorithm and the patient’s intrinsic sinus

but the mean value remained $70%. The reasons for

rhythm. By reducing unnecessary pacing, it helps to

the reduction in AV synchrony could be related to

prevent right ventricular pacinginduced cardiomy-

orthostatic tachycardia and a slight decrease in A4

opathy and to extend battery life.

Steinwender et al.

JACC: CLINICAL ELECTROPHYSIOLOGY VOL. 6, NO. 1, 2020
JANUARY 2020:94–106

Atrioventricular Synchronous Leadless Pacing

Although AV synchrony was excellent at rest, it

Incorporation of the algorithm into the electronics of

decreased during physical activity. Two phenomena

an upgraded leadless device could reduce the current

contributed to this effect by hampering detection of

drain, allowing long-term implantation. For such a

atrial contraction. First, an increase in heart rate with

future device, it will be important to assess the

these maneuvers led to fusion of the atrial and ven-

robustness of ambulatory AV synchrony over real-

tricular components of the accelerometer signals.

world conditions and demonstrate that AV synchrony

Second, additional accelerations caused by body

is maintained continuously over time. Symptomatic

motion were superimposed on the intra-cardiac sig-

and functional assessment data were not collected;

nals. To overcome the decreased AV synchrony dur-

therefore, determination of the precise amount of AV

ing exercise, the activity mode switch (Figure 5B) was

synchrony required to avoid symptoms or maintain

implemented in the MARVEL 2 algorithm. When

appropriate cardiac performance was not assessed.

detecting a signiﬁcant difference between the tracked
sinus rate and heart rate suggested by the pacemaker’s rate response function, VDD mode automatically switched to VVIR, and the pacing rate was
slowly raised to the sensor rate level. Loss of AV
synchrony due to activity mode switching might be
seen as a downside of the MARVEL 2 algorithm;
however, it was previously shown that the heart rate
itself contributed much more to cardiac output at

CONCLUSIONS
Accelerometer-based atrial sensing with a novel,
automated,

enhanced

algorithm

signiﬁcantly

improved AV synchrony and stroke volume in patients
with sinus rhythm and AV block implanted with a
single-chamber leadless pacemaker in the right
ventricle.

higher heart rates than AV synchrony (12,13). Impor-
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associated with a leadless device. In the Micra global
clinical trials, in which only VVI(R) pacing was
delivered, approximately one-third of patients had
normal sinus rhythm, which suggests that physicians
were willing to sacriﬁce synchrony for the beneﬁts of
leadless pacemakers (3). Therefore, selection of this
pacing mode will require a consideration of the beneﬁts of leadless pacing versus the patient’s need for
even higher degrees of AV synchrony.

PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: The enhanced
MARVEL 2 algorithm allowed for AV synchronous ventricular
pacing with a leadless pacemaker in patients with normal sinus
activity and complete heart block. The algorithm worked safely
and robustly, even when changing posture or during physical
activity. An increase in stroke volume was observed with AV

STUDY LIMITATIONS. The observational period and

sample size were limited and might not reﬂect the total
variability of use conditions in the long term. Thus,
results must be conﬁrmed in larger patient populations with longer follow-up. The downloadable
nature of the algorithm increased current drain by
approximately 100, precluding continuous longterm AV synchrony evaluation or the use of the
algorithm

in existing implanted Micra devices.

synchronous pacing using the enhanced MARVEL 2 algorithm
compared with VVI pacing.
TRANSLATIONAL OUTLOOK: Until now, leadless pacemakers
have only been capable of single-chamber pacing (VVI/R). If
implemented in clinical practice, this new technology will help
to further expand the spectrum of patients who might be
eligible for leadless pacing.

105

106

Steinwender et al.

JACC: CLINICAL ELECTROPHYSIOLOGY VOL. 6, NO. 1, 2020
JANUARY 2020:94–106

Atrioventricular Synchronous Leadless Pacing

REFERENCES
1. Udo EO, Zuithoff NP, van Hemel NM, et al.
Incidence and predictors of short- and long-term
complications in pacemaker therapy: the FOLLOWPACE study. Heart Rhythm 2012;9:728–35.

treated with ventricular pacing as compared with
dual-chamber pacing. Pacemaker Selection in the
Elderly Investigators. N Engl J Med 1998;338:
1097–104.

2. Duray GZ, Ritter P, El-Chami M, et al. Long-term
performance of a transcatheter pacing system: 12month results from the Micra Transcatheter Pacing Study. Heart Rhythm 2017;14:702–9.

8. Nielsen JC, Andersen HR, Thomsen PE, et al.
Heart failure and echocardiographic changes during long-term follow-up of patients with sick sinus
syndrome randomized to single-chamber atrial or

3. El-Chami MF, Al-Samadi F, Clementy N, et al.
Updated performance of the Micra transcatheter

ventricular pacing. Circulation 1998;97:987–95.

pacemaker in the real-world setting: a comparison
to the investigational study and a transvenous
historical control. Heart Rhythm 2018;15:1800–7.
4. Reynolds D, Duray GZ, Omar R, et al. A leadless
intracardiac transcatheter pacing system. N Engl J
Med 2016;374:533–41.

9. Chinitz L, Ritter P, Khelae SK, et al. Accelerometer-based atrioventricular synchronous pacing
with a ventricular leadless pacemaker: results
from the Micra atrioventricular feasibility studies.
Heart Rhythm 2018;15:1363–71.

5. Greenspon AJ, Patel JD, Lau E, et al. Trends in
permanent pacemaker implantation in the United
States from 1993 to 2009: increasing complexity

10. Garweg C, Splett V, Sheldon TJ, et al. Behavior
of leadless AV synchronous pacing during atrial
arrhythmias and stability of the atrial signals over
time-results of the MARVEL Evolve subanalysis.
Pacing Clin Electrophysiol 2019;42:381–7.

of patients and procedures. J Am Coll Cardiol
2012;60:1540–5.

11. Stack MF, Rader B, Sobol BJ, Farber SJ,
Eichna LW. Cardiovascular hemodynamic functions

6. Lamas GA, Ellenbogen KA. Evidence base for
pacemaker mode selection: from physiology to
randomized trials. Circulation 2004;109:443–51.

in complete heart block and the effect of isopropylnorepinephrine.
Circulation
1958;17:
526–36.

7. Lamas GA, Orav EJ, Stambler BS, et al. Quality
of life and clinical outcomes in elderly patients

12. Ausubel K, Steingart RM, Shimshi M,
Klementowicz P, Furman S. Maintenance of

exercise stroke volume during ventricular versus
atrial synchronous pacing: role of contractility.
Circulation 1985;72:1037–43.
13. Benditt DG, Milstein S, Buetikofer J,
Gornick CC, Mianulli M, Fetter J. Sensor-triggered,
rate-variable cardiac pacing. Current technologies
and clinical implications. Ann Intern Med 1987;
107:714–24.
14. Antonioli GE, Ansani L, Barbieri D, Guardigli G,
Percoco GF, Toselli T. Italian multicenter study on
a single lead VDD pacing system using a narrow
atrial dipole spacing. Pacing Clin Electrophysiol
1992;15:1890–3.
15. Folino AF, Buja G, Ruzza L, Nava A. Long-term
follow-up of patients with single lead VDD stimulation. Pacing Clin Electrophysiol 1994;17:
1854–8.

KEY WORDS atrioventricular synchrony,
AV block, leadless pacemaker

A PPE NDI X For expanded Methods and
Results sections as well as supplemental
ﬁgures, please see the online version of this
paper.

